1. Emerging Considerations in the Use of Immune Checkpoint Inhibitors: HCC

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Background

4. T-Cell Activation and Exhaustion

5. Nivolumab: PD-1 Inhibitor

6. Ongoing Questions

7. Nivolumab: Dose-Escalation Phase

8. Nivolumab: Dose-Expansion Phase

9. Overall Survival

10. Phase 3 Trials

11. Pembrolizumab: PD-1 Inhibitor

12. Combination Therapy

13. Targeting Multiple Checkpoints

14. Exploring Outcomes

15. Exploring Outcomes (cont)

16. Case Study

17. Deciding to Treat

18. Immune-Related Adverse Events

19. Immune-Related Adverse Events (cont)

20. The Future

21. Abbreviations

22. Abbreviations (cont)